New blood test may predict bleeding danger for cancer patients on clot drugs

NCT ID NCT06386107

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Saint Etienne Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 25, 2026 · Updated 2 times

Summary

This study looks at whether a special blood test, called a thrombin generation assay, can predict bleeding risk in cancer patients who are taking blood thinners for blood clots. Researchers will follow 212 patients for 6 months, measuring their blood's clotting ability and tracking any bleeding events. The goal is to see if this test can help doctors choose safer treatments for cancer-associated thrombosis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: Thrombin Generation Assay (blood test)
What this could lead to: If successful, this could lead to a blood test that helps doctors predict bleeding risk in cancer patients on anticoagulants, allowing safer treatment choices.
What could go wrong: This is an observational study, not a treatment trial. The test may not reliably predict bleeding, and results may not change clinical practice without further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 212 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with active cancer, as defined by current French recommendations (Mahé I et al Rev Mal Respir 2021) * Presenting acute proximal deep vein thrombosis of the lower limb (DVT) and/or proximal pulmonary embolism (at least segmental) (PE), confirmed by objective tests (Doppler ultrasound in the event of DVT; lung scintigraphy or CT scan in the event of PE) * No contraindication for anticoagulant treatment at a curative dose at the time of inclusion Exclusion Criteria: * Patients participating in a therapeutic clinical trial with a blinded therapy or an open-label therapeutic trial who are included in the experimental treatment group. * Patients already on anticoagulant at a curative dose for valvular or rhythmic embolic disease or a history of venous thromboembolic disease * Hematological malignancies * Patients with a contraindication to anticoagulant treatment on inclusion * Patient whose relay by DOAC has already been carried out.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm pulmonary embolism thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Pulmonary embolism Thrombosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

4 sites. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

New blood test may predict bleeding danger for cancer patients on clot drugs

What the study statuses mean